echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > JAMA Netw Open: The best initial treatment for advanced oropharyngeal squamous cell carcinoma?

    JAMA Netw Open: The best initial treatment for advanced oropharyngeal squamous cell carcinoma?

    • Last Update: 2021-06-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Targeted radiotherapy and chemotherapy (Definitive chemoradiotherapy) and upfront surgical treatment (Upfront surgical treatment) are both considered to be the standard regimen for advanced oropharyngeal squamous cell carcinoma.
    However, the best primary treatment for advanced oropharyngeal squamous cell carcinoma remains unclear.

    This study aims to compare the efficacy of targeted radiotherapy and chemotherapy and preoperative treatment for advanced oropharyngeal squamous cell carcinoma.

    This is a retrospective comparative analysis of efficacy, including stage III or IV oropharyngeal squamous cell carcinoma diagnosed from 2007 to 2015 (excluding patients with T4b or N3 stage); from June 2019 to December 2020 Perform data analysis monthly.
    The primary endpoint is overall survival.
    The secondary endpoints are progression-free survival, local recurrence-free survival, and distant metastasis-free survival.

    A total of 1180 patients (89.
    1% males, average 54.
    59 years old)
    were recruited :
    694 patients (58.
    8%) in the
    targeted radiotherapy
    group and 486 patients (41.
    2%) in the
    preoperative treatment group .
    Most patients had primary tonsil tumors (712 cases [60.
    3%]), intermediate histology (604 cases [51.
    2%]), clinical N2 stage (858 cases [72.
    7%]), clinical stage IVA disease stage (938 cases) ).

    1180 patients in the targeted radiotherapy and chemotherapy group, 694 patients in the preoperative treatment group, 486 patients

    Overall survival rate of the two groups of patients

    Overall survival rate of the two groups of patients

    The median follow-up was 3.
    62
    years (interquartile range: 1.
    63-5.
    47).
    Previous surgical treatment was the main treatment and was associated with a reduced risk of death during the study period (hazard ratio [HR] 0.
    81; 95% CI, 0.
    69-0.
    97; P=0.
    02).
    However, after grouping according to age, location, histological grade, and T/N, pre-surgical treatment was no longer associated with a reduced risk of death during the study period (HR 0.
    96; 95% CI, 0.
    80-1.
    16; P=0.
    70).

    Median follow-up was 3.
    62 years

    Progression-free survival of the two groups of patients

    Progression-free survival of the two groups of patients

    The progression-free survival of the preoperative surgical treatment group was worse than that of the targeted radiotherapy and chemotherapy group (HR 1.
    64; 95% CI, 1.
    09-2.
    46; P=0.
    02), and this difference still exists after calibration according to other prognostic factors ( Such as age, tumor location, etc.
    ) (HR 1.
    72; 95% CI, 1.
    12-2.
    66; P=0.
    01).

    The progression-free survival of the preoperative surgical treatment group was worse than that of the targeted radiotherapy and chemotherapy group

    Local recurrence-free survival of the two groups of patients

    Local recurrence-free survival of the two groups of patients

    In summary, the results of this study show that after calibration based on prognostic-related baseline factors, the efficacy of targeted radiotherapy and chemotherapy can be comparable to that of previous surgical treatment.
    All in all, in this study, the efficacy of targeted radiotherapy and chemotherapy and preoperative treatment in advanced oropharyngeal squamous cell carcinoma is still the same.

    All in all, in this study, the efficacy of targeted radiotherapy and chemotherapy and preoperative treatment in advanced oropharyngeal squamous cell carcinoma is still the same.
    All in all, in this study, the efficacy of targeted radiotherapy and chemotherapy and preoperative treatment in advanced oropharyngeal squamous cell carcinoma is still the same.

    Original source:

    Original source:

    Tsai Mu-Hung,Cheng Yung-Jen,Pao Tzu-Hui et al.
    Association of Primary Treatment Modality for Advanced-Stage Oropharyngeal Squamous Cell Carcinoma With Survival Outcomes .
    [J].
    JAMA Netw Open, 2021, 4: e2112067.

    Modality for Treatment of Primary Association or Advanced Oropharyngeal Squamous the Cell-Journal of the Stage With Survival Outcomes, JAMA

    in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.